Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Abstract Background In patients with BRAFV600 mutated unresectable stage IIIc or metastatic melanoma, molecular targeted therapy with combined BRAF/MEK-inhibitor vemurafenib plus cobimetinib has shown a significantly improved progression-free survival and overall survival compared to treatment with...

Full description

Bibliographic Details
Main Authors: Bernies van der Hiel, John B.A.G. Haanen, Marcel P.M. Stokkel, Daniel S. Peeper, Connie R. Jimenez, Jos H. Beijnen, Bart A. van de Wiel, Ronald Boellaard, Alfons J.M. van den Eertwegh, REPOSIT study group
Format: Article
Language:English
Published: BMC 2017-09-01
Series:BMC Cancer
Subjects:
Stage IIIc/IV melanoma
Resistance
BRAF inhibitor
MEK inhibitor
18F-FDG
18F-FLT
Online Access:http://link.springer.com/article/10.1186/s12885-017-3626-5

Internet

http://link.springer.com/article/10.1186/s12885-017-3626-5

Similar Items